Epic Sciences is changing the paradigm of cancer management by developing clinical solutions which enable earlier diagnosis, better staging, improve therapeutic selection, and accelerate drug development through enumeration and molecular characterization of rare cells, including circulating tumor cells (CTCs). Our mission is to improve patient lives by enabling precision medicine with non-invasive, real-time tests that profile rare cancer cells in cancer throughout the course of treatment. Epic’s technology and partnerships with leading pharmaceutical companies and cancer centers around the world help match patients to targeted therapies and monitor for drug resistance so that the best treatment path can be chosen at every clinical decision point. The Epic CTC Platform is designed with integrated downstream capabilities to evaluate protein (IF) and genetic (FISH, NGS) biomarkers at single cell resolution. Our detection and characterization platform is the only commercially available technology capable of identifying varieties of CTCs. With capabilities that allow for the systematic analysis of individual CTCs for genetic and proteomic aberrations, our platform provides near real-time information about each different cellular population before, during and after treatments.